Polygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives

Journal of Psychiatric Research

Volumn 77, Issue , 2016, Pages 52-58

  Padmanabhan, Jaya L ^a,b   Nanda, Pranav ^c   Tandon, Neeraj ^a,d   Mothi, Suraj S ^a   Bolo, Nicolas ^a   McCarroll, Steven ^e,f   Clementz, Brett A ^i,j   Gershon, Elliot S ^g   Pearlson, Godfrey D ^h,k   Sweeney, John A ^l   Tamminga, Carol A ^l   Keshavan, Matcheri S ^a,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MCLEAN HOSPITAL   (United States)

^c Columbia University Medical Center ^*  (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h INSTITUTE OF LIVING   (United States)

ⁱ University of Georgia   (United States)

^j UNIVERSITY OF GEORGIA   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

Bipolar; Diabetes; Genetic; Polygenic; Psychosis; Schizophrenia

Indexed keywords

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; BIPOLAR I DISORDER; CAUCASIAN; CONSANGUINITY; CONTROLLED STUDY; DSM-IV; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYGENIC RISK SCORE; PREVALENCE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SELF REPORT; DIABETES MELLITUS, TYPE 2; FAMILY; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MIDDLE AGED; MULTIFACTORIAL INHERITANCE; PSYCHOTIC DISORDERS; RISK; STATISTICAL MODEL;

NEUROLEPTIC AGENT;

ADULT; AFRICAN AMERICANS; ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIFACTORIAL INHERITANCE; PREVALENCE; PSYCHOTIC DISORDERS; RISK; SCHIZOPHRENIA; SELF REPORT;

EID: 84960445829     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2016.02.015     Document Type: Article

References (62)

1. Anderson C.A., Pettersson F.H., Clarke G.M., Cardon L.R., Morris A.P., Zondervan K.T. Data quality control in genetic case-control association studies. Nat. Protoc. 2010, 5:1564-1573.
2. Bak M., Fransen A., Janssen J., van Os J., Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014, 9:e94112.
3. Bly M.J., Taylor S.F., Dalack G., Pop-Busui R., Burghardt K.J., Evans S.J., et al. Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. Bipolar Disord. 2014, 16:277-288.
4. Brancati F.L., Kao W.H., Folsom A.R., Watson R.L., Szklo M. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 2000, 283:2253-2259.
5. Broad Institute. PsychChip Resources. , last accessed 1/1/2016. https://www.med.unc.edu/pgc/psychchip.
6. Bushe C., Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br. J. Psychiatry Suppl. 2004, 47:S67-S71.
7. Carter J.S., Pugh J.A., Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann. Intern. Med. 1996, 125:221-232.
8. Chang C.C., Chow C.C., Tellier L.C., Vattikuti S., Purcell S.M., Lee J.J. Second-generation PLINK: rising to the challenge of larger and richer datasets. GigaScience 2015, 4:7.
9. Chen S., Broqueres-You D., Yang G., Wang Z., Li Y., Wang N., et al. Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia. Psychiatry Res. 2013, 210:825-829.
10. Cheng C.Y., Reich D., Haiman C.A., Tandon A., Patterson N., Selvin E., et al. African ancestry and its correlation to type 2 diabetes in African Americans: a genetic admixture analysis in three U.S. population cohorts. PLoS One 2012, 7:e32840.
11. Cross-Disorder Group of the Psychiatric Genomics C, Lee S.H., Ripke S., Neale B.M., Faraone S.V., Purcell S.M., et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 2013, 45:984-994.
12. Delaneau O., Marchini J., Zagury J.F. A linear complexity phasing method for thousands of genomes. Nat. methods 2012, 9:179-181.
13. Delaneau O., Zagury J.F., Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. Nat. methods 2013, 10:5-6.
14. Mahajan A., et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat. Genet. 2014, 46:234-244. DIAbetes Genetics Replication Meta-analysis Consortium, Asian Genetic Epidemiology Network Type 2 Diabetes Consortium, South Asian Type 2 Diabetes Consortium, Mexican American Type 2 Diabetes Consortium, Type 2 Diabetes Genetic Exploration by Next-generation sequencing in multi-Ethnic Samples ConsortiumAsian Genetic Epidemiology Network Type 2 Diabetes Consortium, South Asian Type 2 Diabetes Consortium, Mexican American Type 2 Diabetes Consortium, Type 2 Diabetes Genetic Exploration by Next-generation sequencing in multi-Ethnic Samples Consortium.
15. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 2000, 26:903-912.
16. Dwyer D.S., Pinkofsky H.B., Liu Y., Bradley R.J. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog. Neuropsychopharmacol. Biol. Psychiatry 1999, 23:69-80.
17. Fernandez-Egea E., Miller B., Bernardo M., Donner T., Kirkpatrick B. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr. Res. 2008, 98:302-306.
18. First M.B., Spitzer Robert L., Miriam Gibbon, Williams Janet B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders 2002, Biometrics Research, New York State Psychiatric Institute, New York, Research Version, Non-patient Edition.
19. Foley D.L., Mackinnon A., Morgan V.A., Watts G.F., Castle D.J., Waterreus A., et al. Common familial risk factors for schizophrenia and diabetes mellitus. Aust. N. Z. J. Psychiatry 2015 Jul 24.
20. Haiman C.A., Fesinmeyer M.D., Spencer K.L., Buzkova P., Voruganti V.S., Wan P., et al. Consistent directions of effect for established type 2 diabetes risk variants across populations: the population architecture using Genomics and Epidemiology (PAGE) Consortium. Diabetes 2012, 61:1642-1647.
21. Hansen T., Ingason A., Djurovic S., Melle I., Fenger M., Gustafsson O., et al. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol. Psychiatry 2011, 70:59-63.
22. Holt R.I., Mitchell A.J. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat. Rev. Endocrinol. 2015, 11:79-89.
23. Howie B., Fuchsberger C., Stephens M., Marchini J., Abecasis G.R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat. Genet. 2012, 44:955-959.
24. Howie B., Marchini J., Stephens M. Genotype imputation with thousands of genomes. G3 2011, 1:457-470.
25. Howie B.N., Donnelly P., Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009, 5:e1000529.
26. Irvin M.R., Wiener H.W., Perry R.P., Savage R.M., Go R.C. Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder. Schizophr. Res. 2009, 114:50-56.
27. Kirkpatrick B., Miller B.J., Garcia-Rizo C., Fernandez-Egea E., Bernardo M. Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits?. Schizophr. Bull. 2012, 38:280-284.
28. Lin P.I., Shuldiner A.R. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr. Res. 2010, 123:234-243.
29. Maier W., Lichtermann D., Minges J., Heun R. Personality disorders among the relatives of schizophrenia patients. Schizophr. Bull. 1994, 20:481-493.
30. Marchini J., Howie B. Genotype imputation for genome-wide association studies. Nat. Rev. Genet. 2010, 11:499-511.
31. Marshall M.C. Diabetes in African Americans. Postgrad. Med. J. 2005, 81:734-740.
32. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostatic model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
33. Meda S.A., Ruano G., Windemuth A., O'Neil K., Berwise C., Dunn S.M., et al. Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E2066-E2075.
34. Menke A., Orchard T.J., Imperatore G., Bullard K.M., Mayer-Davis E., Cowie C.C. The prevalence of type 1 diabetes in the United States. Epidemiology 2013, 24:773-774.
35. Mizuki Y., Takaki M., Okahisa Y., Sakamoto S., Kodama M., Ujike H., et al. Human Rho guanine nucleotide exchange factor 11 gene is associated with schizophrenia in a Japanese population. Hum. Psychopharmacol. 2014, 29:552-558.
36. Morris A.P., Voight B.F., Teslovich T.M., Ferreira T., Segre A.V., Steinthorsdottir V., et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 2012, 44:981-990.
37. Mothi S.S., Tandon N., Padmanabhan J., Mathew I.T., Clementz B., Tamminga C., et al. Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders. Schizophr. Res. 2015, 165:103-107.
38. Mukherjee S., Schnur D.B., Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989, 1:495.
39. Narayanan B., Ethridge L.E., O'Neil K., Dunn S., Mathew I., Tandon N., et al. Genetic sources of subcomponents of event-related potential in the dimension of psychosis analyzed from the B-SNIP study. Am. J. Psychiatry 2015, 172:466-478.
40. Ng M.C., Shriner D., Chen B.H., Li J., Chen W.M., Guo X., et al. Meta-analysis of genome-wide association studies in African Americans provides insights into the genetic architecture of type 2 diabetes. PLoS Genet. 2014, 10:e1004517.
41. Nielsen J., Skadhede S., Correll C.U. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology 2010, 35:1997-2004.
42. Pastorino S., Richards M., Hardy R., Abington J., Wills A., Kuh D., et al. Validation of self-reported diagnosis of diabetes in the 1946 British birth cohort. Prim. care diabetes 2015, 9:397-400.
43. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
44. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
45. Regenold W.T., Thapar R.K., Marano C., Gavirneni S., Kondapavuluru P.V. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J. Affect Disord. 2002, 70:19-26.
46. Robbins J.M., Vaccarino V., Zhang H., Kasl S.V. Excess type 2 diabetes in African-American women and men aged 40-74 and socioeconomic status: evidence from the Third National Health and Nutrition Examination Survey. J. Epidemiol. community health 2000, 54:839-845.
47. Roy T., Lloyd C.E. Epidemiology of depression and diabetes: a systematic review. J Affect Disord 2012, (Suppl. S8-21):142.
48. Ruzickova M., Slaney C., Garnham J., Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can. J. Psychiatry 2003, 48:458-461.
49. Ryan M., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160:284-289.
50. Schizophrenia Working Group of the Psychiatric Genomics C Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427.
51. Selim A.J., Fincke G., Ren X.S., Lee A., Rogers W.H., Miller D.R., et al. Comorbidity assessments based on patient report: results from the Veterans Health Study. J. Ambul. care Manag. 2004, 27:281-295.
52. Sengupta S., Parrilla-Escobar M.A., Klink R., Fathalli F., Ying Kin N., Stip E., et al. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls?. Schizophr. Res. 2008, 102:329-336.
53. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 2002, 159:561-566.
54. Shiloah E., Witz S., Abramovitch Y., Cohen O., Buchs A., Ramot Y., et al. Effect of acute psychotic stress in nondiabetic subjects on beta-cell function and insulin sensitivity. Diabetes care 2003, 26:1462-1467.
55. Smith M., Hopkins D., Peveler R.C., Holt R.I., Woodward M., Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry 2008, 192:406-411.
56. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabetic medicine. a J. Br. Diabet. Assoc. 2007, 24:481-485.
57. Stringer S., Kahn R.S., de Witte L.D., Ophoff R.A., Derks E.M. Genetic liability for schizophrenia predicts risk of immune disorders. Schizophr. Res. 2014, 159:347-352.
58. Teff K.L., Rickels M.R., Grudziak J., Fuller C., Nguyen H.L., Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 2013, 62:3232-3240.
59. Vassy J.L., Hivert M.F., Porneala B., Dauriz M., Florez J.C., Dupuis J., et al. Polygenic type 2 diabetes prediction at the limit of common variant detection. Diabetes 2014, 63:2172-2182.
60. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Naveen M.N., Thirthall J., Gangadhar B.N., et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am. J. Psychiatry 2007, 164:1557-1560.
61. Weston-Green K., Huang X.F., Lian J., Deng C. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur. Neuropsychopharmacol. 2012, 22:364-373.
62. Zhang X., Hui L., Liu Y., Wang Z.Q., You Y., Miao L.N., et al. The type 2 diabetes mellitus susceptibility gene IGF2BP2 is associated with schizophrenia in a Han Chinese population. J. Clin. Psychiatry 2013, 74. e287-92.